In patients without IBD, the overall rate of GI adverse events of any grade was 11% (1,283 patients had a GI adverse event of the 11,377 patients who received either CTLA-4 [18%] or PD-1/PD-L1 [82%] inhibitors). The gene discussed is PDCD1; the disease is inflammatory bowel disease.